clinical trial · NCT07532252

Daridorexant for Alcohol Use Disorder

Johns Hopkins University →·phase2·not yet recruiting·n = 150

Alcohol Use DisorderDaridorexant 50 mgPlacebo

brief summary

This study will test whether the dual orexin receptor antagonist (DORA) daridorexant reduces alcohol craving and use and improves total sleep time among patients with co-occurring alcohol use disorder and sleep disturbance. The study will assess the role of the orexin system in modulating alcohol craving and use in a real-world treatment setting.

started

Jan 1, 2027

primary completion

Aug 1, 2030

completion

Feb 1, 2031

last updated

Apr 20, 2026

official title

A Double-Blind Randomized Controlled Trial of Daridorexant for Alcohol Use Disorder

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol